Thierry Gorlia Selected Research

Procarbazine (Matulane)

10/2022	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
1/2020	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
3/2016	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
11/2013	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
10/2013	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.
1/2013	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
1/2013	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
7/2011	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
3/2010	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
12/2009	MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thierry Gorlia Research Topics

Disease

47	Neoplasms (Cancer) 12/2022 - 03/2005
44	Glioblastoma (Glioblastoma Multiforme) 12/2022 - 03/2005
18	Glioma (Gliomas) 01/2022 - 10/2008
7	Brain Neoplasms (Brain Tumor) 10/2022 - 10/2008
7	Astrocytoma (Pilocytic Astrocytoma) 01/2022 - 06/2006
6	Oligodendroglioma 11/2016 - 06/2006
3	Necrosis 11/2019 - 06/2012
3	Disease Progression 09/2014 - 09/2009
2	Neutropenia 01/2022 - 09/2014
2	Lymphopenia (Lymphocytopenia) 01/2022 - 09/2014
2	Fatigue 01/2022 - 11/2016
2	Thrombocytopenia (Thrombopenia) 01/2022 - 09/2014
2	Neoplasm Metastasis (Metastasis) 05/2010 - 10/2007
2	Colorectal Neoplasms (Colorectal Cancer) 06/2009 - 08/2006
1	Meningioma (Meningiomas) 01/2022
1	Anemia 01/2022
1	Central Nervous System Neoplasms 01/2022
1	Vision Disorders (Hemeralopia) 01/2021
1	Hypersensitivity (Allergy) 01/2020
1	Diabetes Mellitus 01/2020
1	Nausea 01/2020
1	Vomiting 01/2020
1	Hemorrhage 01/2018
1	Infections 11/2016
1	Virus Diseases (Viral Diseases) 11/2016
1	Chronic Hepatitis B 11/2016
1	HIV Infections (HIV Infection) 11/2016
1	Epilepsy (Aura) 03/2016
1	Status Epilepticus (Complex Partial Status Epilepticus) 11/2013
1	Residual Neoplasm 11/2013
1	Carcinoma (Carcinomatosis) 05/2010

Drug/Important Bio-Agent (IBA)

35	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 03/2005
17	Lomustine (CCNU)FDA Link 10/2022 - 06/2006
12	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 06/2006
12	Procarbazine (Matulane)FDA Link 10/2022 - 06/2006
7	Bevacizumab (Avastin)FDA Link 01/2022 - 03/2016
6	MethyltransferasesIBA 01/2019 - 10/2008
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 07/2011
5	Biomarkers (Surrogate Marker)IBA 11/2020 - 08/2008
4	epidermal growth factor receptor VIIIIBA 12/2022 - 03/2009
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 07/2011
4	depatuxizumab mafodotinIBA 08/2021 - 01/2020
4	ErbB Receptors (EGF Receptor)IBA 01/2020 - 06/2008
4	CilengitideIBA 05/2018 - 09/2014
4	Fluorouracil (Carac)FDA LinkGeneric 06/2009 - 08/2006
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2020
3	O-(6)-methylguanineIBA 01/2019 - 03/2016
3	IntegrinsIBA 05/2018 - 09/2014
3	Biological ProductsIBA 12/2009 - 06/2008
2	Pharmaceutical PreparationsIBA 01/2021 - 05/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 01/2010
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2009 - 08/2006
2	Leucovorin (Folinic Acid)FDA Link 06/2009 - 08/2006
2	Carmustine (FIVB)FDA Link 03/2009 - 06/2008
2	Cisplatin (Platino)FDA LinkGeneric 10/2007 - 01/2002
1	TrabectedinIBA 01/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	GadoliniumIBA 12/2021
1	Contrast MediaIBA 12/2021
1	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2020
1	Oxygen (Dioxygen)IBA 10/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	LigandsIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	Metformin (Glucophage)FDA LinkGeneric 01/2020
1	EpitopesIBA 01/2020
1	monomethylauristatin FIBA 01/2020
1	NucleotidesIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2018
1	Angiotensin II Type 1 Receptor BlockersIBA 05/2018
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2018
1	Angiotensin Receptor AntagonistsIBA 05/2018
1	vasectrin IIIIBA 01/2018
1	AnticoagulantsIBA 01/2018
1	temsirolimus FDA Link 10/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2016
1	Valproic Acid (Depakote)FDA LinkGeneric 03/2016
1	Levetiracetam (Keppra)FDA LinkGeneric 03/2016
1	Anticonvulsants (Antiepileptic Drugs)IBA 03/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	SteroidsIBA 01/2016
1	Dasatinib (BMS 354825)FDA Link 12/2012
1	alpha-internexinIBA 07/2011
1	Indomethacin (Indometacin)FDA LinkGeneric 07/2010
1	O(6)-Methylguanine-DNA MethyltransferaseIBA 07/2010
1	Epirubicin (Ellence)FDA LinkGeneric 05/2010
1	Isoniazid (Ftivazide)FDA LinkGeneric 05/2010

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 10/2022 - 01/2002
27	Radiotherapy 10/2022 - 03/2005
11	Chemoradiotherapy 01/2022 - 06/2008
6	Therapeutics 01/2022 - 08/2006
3	Aftercare (After-Treatment) 01/2021 - 01/2019
3	Precision Medicine 01/2020 - 07/2015
1	Immunotherapy 01/2022
1	Conformal Radiotherapy 01/2021
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021
1	Oral Administration 11/2016